AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30264056
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline solution (Control)
Trial: 26866082
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 20 mcg 2-hourly up to a maximum of 4 doses
Trial: 26866082
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin according to WHO protocol
Trial: 22248659
Drug: Mericitabine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine (500 or 1000 mg, twice daily) plus danoprevir (100 or 200 mg, every 8 hours, or 600 or 900 mg, twice daily)
Trial: 19744259
Drug: Intralesional SSG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional SSG + intramuscular SSG
Trial: 19744259
Drug: Intralesional SSG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional SSG + oral ketoconazole
Trial: 15713352
Drug: Voglibose (0.4-0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.4-0.6 mg/day)
Trial: 12798444
Drug: Fluvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (80 mg slow release matrix tablet, acute application)
Trial: 12798444
Drug: Fluvastatin (2-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (2-month medication regimen)
Trial: 7634730
Drug: Cortisone injection
RxNorm normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone injection with lidocaine
Trial: 7634730
Drug: Cortisone injection
RxNorm normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone injection with bupivacaine
Trial: 7634730
Drug: Cortisone injection
RxNorm normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone injection (regardless of anesthetic)
Trial: 411398
Drug: Aerosolized atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized atropine sulphate (1 mg)
Trial: 411398
Drug: Isoproterenol (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (0.625 mg)
Trial: 411398
Drug: Isoproterenol or
RxNorm normalized name: isoproterenol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol or atropine pre-treatment
Trial: 31585191
Drug: SA3Ag vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA3Ag vaccine (low-dose: 102; mid-dose: 101; high-dose: 101)
Trial: 31585191
Drug: SA3Ag vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA3Ag vaccine (all doses)
Trial: 31585191
Drug: SA3Ag vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA3Ag vaccine (mid-dose and high-dose)
Trial: 31585191
Drug: SA3Ag vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA3Ag vaccine (low-dose and placebo)
Trial: 28842581
Drug: C34-PEG4-Chol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C34-PEG4-Chol (10 mg, 10 mg, and 20 mg)
Trial: 28842581
Drug: C34-PEG4-Chol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C34-PEG4-Chol (10 mg, 20 mg)
Trial: 25757714
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted CBT for psychosis (CaCBTp) plus treatment as usual (TAU)
Trial: 22874661
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise (3 weekly sessions for 12 weeks)
Trial: 22874661
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (1 weekly session for 12 weeks)
Trial: 19788025
Drug: Desloratadine, 5
RxNorm normalized name: Desloratadine, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine, 5 mg daily for 15 days
Trial: 8508863
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg zofenopril once daily
Trial: 3327854
Drug: Flordipine 25
RxNorm normalized name: felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flordipine 25 mg
Trial: 3327854
Drug: Flordipine 50
RxNorm normalized name: felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flordipine 50 mg
Trial: 31279794
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocortisone and 10 mg yohimbine combined
Trial: 27785892
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant IL-2
Trial: 17362456
Drug: 2% lidocaine-soaked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine-soaked sponge (Group L, n = 32)
Trial: 15465617
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of pegylated interferon weekly alone
Trial: 9495509
Drug: Calcium (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1600 mg/day as the citrate)
Trial: 7992293
Drug: Lovastatin (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20, 40 and 80 mg/day)
Trial: 7992293
Drug: Pravastatin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10, 20 and 40 mg/day)
Trial: 1227823
Drug: Betahistidine hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistidine hydrochloride, 4 mg three times daily
Trial: 18492265
Drug: NP 06‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP 06‐1 (370 mg each, two capsules twice daily)
Trial: 8614967
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU of rHuEPO per kg of body weight intravenously twice a week
Trial: 1393034
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of up to 20 mg papaveretum
Trial: 2862523
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of lignocaine and hydrocortisone
Trial: 26963505
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal ring (25 mg), inserted 4-weekly for 12 weeks
Trial: 26963505
Drug: Placebo ring,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ring, inserted 4-weekly for 12 weeks
Trial: 14871462
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g oral moist snuff
Trial: 9137797
Drug: CMF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF treatment in TP-positive tumours
Trial: 25523190
Drug: Stoss vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stoss vitamin D therapy
Trial: 9174681
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg esuprone
Trial: 6367452
Drug: Intravenous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cimetidine (300 mg every six hours)
Trial: 6367452
Drug: Cimetidine tablets
RxNorm normalized name: Cimetidine Tablets
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine tablets (300 mg three times a day and at bedtime)
Trial: 6367452
Drug: Hourly antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly antacids (Mylanta II liquid 30 ml every hour)
Trial: 6367452
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus hourly antacids
Trial: 30811630
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 2g of nanorap formulation (50mg lidocaine + 50mg prilocaine)
Trial: 30811630
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control formulation)
Trial: 30811630
Drug: Nanorap formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanorap formulation
Trial: 25631504
Drug: Metronidazole sustained-release
RxNorm normalized name: metronidazole Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole sustained-release film combined with minocycline hydrochloride
Trial: 22775467
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 820 nm; continuous wave; output power: 50 mW; exposure duration: 5 sec; energy dose: 0.25 J; energy density: 7.96 J/cm(2) for each shot
Trial: 22775467
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (no laser treatment)
Trial: 19879750
Drug: E120 (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E120 (epirubicin 120 mg/m²)
Trial: 19879750
Drug: EC-CMF (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-CMF (epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² followed by CMF)
Trial: 18517036
Drug: Gaboxadol (GBX)
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol (GBX) 15 mg
Trial: 16029679
Drug: 5% niacinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% niacinamide applied twice daily for 12 weeks
Trial: 16029679
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied twice daily for 12 weeks
Trial: 385948
Drug: No immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immunotherapy
Trial: 3312020
Drug: Amoxicillin with
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin with clavulanic acid
Trial: 6339961
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (intensive courses of methotrexate with vincristine and prednisone reinductions and administration of cyclophosphamide)
Trial: 6339961
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (courses of methotrexate alternated with courses of 6‐mercaptopurine during consolidation and intensification therapy)
Trial: 6339961
Drug: Protocol 0276/A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 0276/A (similar to regimen B but with L‐asparaginase and prolonged therapy duration)
Trial: 6339961
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methotrexate and 6‐mercaptopurine
Trial: 30390895
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day of EPA‐enriched oral nutrition supplementation (ONS)
Trial: 20408345
Drug: sublingual latex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual latex extract
Trial: 17223657
Drug: Leflunomide (LEF)
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide (LEF) 20 mg once daily for 24 weeks
Trial: 17078441
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (penetrating needling, scalp acupuncture, strong/electric needling on body points)
Trial: 15220599
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement (InflammEnz, Enzymes, Inc., Parkville, Mo.) - four capsules per day for 7 days
Trial: 10910797
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication follow-up plus a condition designed to control for therapist time and provide environmental changes unrelated to cognitive deficits
Trial: 10910797
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication follow-up only
Trial: 8835112
Drug: ZVD (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZVD (500 mg daily) + rG‐CSF (10 micrograms/Kg/biweekly) + Epo (50 IU/Kg/biweekly)
Trial: 8835112
Drug: ZVD (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZVD (500 mg/day) alone
Trial: 1279214
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg terazosin
Trial: 2897299
Drug: Atenolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (200 mg)
Trial: 28731003
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously every 3 weeks for three cycles followed by Pemetrexed consolidation every 3 weeks for 4 cycles.
Trial: 28731003
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Standard therapy with Etoposide 50 mg/m2 and Cisplatin 50 mg/m2 intravenously every 4 weeks for two cycles followed by two cycles of consolidation platinum-based doublet chemotherapy.
Trial: 28731003
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously.
Trial: 28731003
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Standard therapy with Etoposide and Cisplatin.
Trial: 25111959
Drug: Bendamustine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 120 mg/m2
Trial: 16645967
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate 7.5 mg/week + cyclosporine 2.5 mg/kg/day)
Trial: 16645967
Drug: Monotherapy (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (methotrexate + placebo-cyclosporine)
Trial: 16645967
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate + intraarticular glucocorticoid)
Trial: 16645967
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate + cyclosporine)
Trial: 8983088
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 4 mg/day
Trial: 8983088
Drug: Cortisol (CORT)
RxNorm normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cortisol (CORT) 10 mg/h
Trial: 1457111
Drug: Atracurium (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with desflurane
Trial: 1457111
Drug: Atracurium (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with isoflurane
Trial: 6091501
Drug: Metoclopramide, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide, 10 mg in the morning (Group II)
Trial: 6091501
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg (Group III)
Trial: 6091501
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg and metoclopramide, 10 mg in the morning (Group IV)
Trial: 6091501
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg at bedtime and in the morning (Group V)
Trial: 6091501
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group VI)
Trial: 6091501
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg in the morning (Group VII)
Trial: 6091501
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg and metoclopramide, 10 mg in the morning (Group VIII)
Trial: 6091501
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg at bedtime and in the morning (Group IX)
Trial: 6091501
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group X)
Trial: 27267500
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behavioral therapy (CBT‐E)
Trial: 27467700
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment as usual (TAU‐O)
Trial: 19502285
Drug: Oxytocin 5
RxNorm normalized name: oxytocin 5 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 5 u (first dose)
Trial: 19502285
Drug: Oxytocin 5
RxNorm normalized name: oxytocin 5 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 5 u (second dose)
Trial: 15172774
Drug: amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amphotericin B plus flucytosine (100 mg/kg daily)
Trial: 15172774
Drug: amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amphotericin B (0.7 mg/kg daily)
Trial: 15172774
Drug: amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amphotericin B plus fluconazole (400 mg daily)
Trial: 15172774
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy with amphotericin B, flucytosine, and fluconazole
Trial: 8259900
Drug: Quantitative progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quantitative progressive exercise muscle rehabilitation program (QPE) added to physical therapy (PT) program
Trial: 21956168
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg daily for 3 months
Trial: 18684743
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneously every other week for up to 120 weeks
Trial: 17250578
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine dentifrice gel (CHX‐DGel, Perio.Aid)
Trial: 15710852
Drug: Rasagiline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1.0 mg/d
Trial: 15710852
Drug: Rasagiline 0.5
RxNorm normalized name: rasagiline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 0.5 mg/d
Trial: 15710852
Drug: Rasagiline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1.0 mg/d vs Placebo
Trial: 15710852
Drug: Rasagiline 0.5
RxNorm normalized name: rasagiline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 0.5 mg/d vs Placebo
Trial: 12043767
Drug: Anabolic steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic steroids, vitamin D and calcium
Trial: 7861490
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg, orally 3 times a day for 4 days)
Trial: 6791203
Drug: Lentizol (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentizol (sustained-release amitriptyline)
Trial: 6791203
Drug: Ordinary amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary amitriptyline tablets
Trial: 30670228
Drug: Dual-task aquatic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-task aquatic exercise program, twice a week for 10 weeks, 40 minutes per session in a heated pool (33°C)
Trial: 28507373
Drug: LASER therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LASER therapy
Trial: 28713116
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise and LASER therapy
Trial: 26137324
Drug: Lithium (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (n = 23, 0.79 ± 0.15 mEq/L)
Trial: 26137324
Drug: Valproate (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (n = 13, 79.6 ± 12.4 mg/mL)
Trial: 17205445
Drug: E-test antibiotic
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-test antibiotic strips (AB Biodisk) applied directly on respiratory tract samples
Trial: 10891925
Drug: m-chlorophenylpiperazine (mCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (mCPP) 0.5 mg/kg